Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.

Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.

J Oncol Pharm Pract. 2016 Jan 13. pii: 1078155215625459. [Epub ahead of print] Review.

PMID:
26769697
2.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology.

J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13. Review.

PMID:
26169616
3.

The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.

Wang L, Baser O, Kutikova L, Page JH, Barron R.

Support Care Cancer. 2015 Nov;23(11):3131-40. doi: 10.1007/s00520-015-2686-9. Epub 2015 Mar 29.

4.

Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

Kim MG, Han N, Lee EK, Kim T.

Bone Marrow Transplant. 2015 Apr;50(4):523-30. doi: 10.1038/bmt.2014.297. Epub 2015 Jan 12. Review.

PMID:
25581410
5.

Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.

Hsu JW, Wingard JR, Logan BR, Chitphakdithai P, Akpek G, Anderlini P, Artz AS, Bredeson C, Goldstein S, Hale G, Hematti P, Joshi S, Kamble RT, Lazarus HM, O'Donnell PV, Pulsipher MA, Savani BN, Schears RM, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2015 Jan;21(1):165-71. doi: 10.1016/j.bbmt.2014.10.007. Epub 2014 Oct 12.

6.

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.

Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z.

Support Care Cancer. 2015 Feb;23(2):525-45. doi: 10.1007/s00520-014-2457-z. Epub 2014 Oct 7. Review.

PMID:
25284721
7.

Myeloid growth factors.

Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1266-90.

PMID:
24142827
8.

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S.

Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17. Review.

9.

Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.

Hirsch BR, Lyman GH.

Pharmacoeconomics. 2012 Jun 1;30(6):497-511. doi: 10.2165/11590130-000000000-00000. Review.

PMID:
22540394
10.

Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies.

Sheppard D, Bredeson C, Allan D, Tay J.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1191-203. doi: 10.1016/j.bbmt.2012.01.008. Epub 2012 Jan 16. Review.

11.

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.

Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL.

BMC Cancer. 2011 Sep 23;11:404. doi: 10.1186/1471-2407-11-404. Review.

12.

Consistency between direct and indirect trial evidence: is direct evidence always more reliable?

Madan J, Stevenson MD, Cooper KL, Ades AE, Whyte S, Akehurst R.

Value Health. 2011 Sep-Oct;14(6):953-60. doi: 10.1016/j.jval.2011.05.042. Epub 2011 Jul 28.

13.

A systematic review of available clinical evidence - filgrastim compared with lenograstim.

Sourgens H, Lefrère F.

Int J Clin Pharmacol Ther. 2011 Aug;49(8):510-8. Review.

14.

Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.

Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, Pane F, Tura S.

Haematologica. 2011 Jul;96(7):937-42. doi: 10.3324/haematol.2011.041210. No abstract available.

15.

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.

Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R.

Value Health. 2011 Jun;14(4):465-74. doi: 10.1016/j.jval.2010.10.037. Epub 2011 Apr 22.

16.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer.

Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20.

PMID:
21095116
17.

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

Crawford J, Caserta C, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v248-51. doi: 10.1093/annonc/mdq195. No abstract available.

18.

Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD.

Trivedi M, Martinez S, Corringham S, Medley K, Ball ED.

J Oncol Pharm Pract. 2011 Jun;17(2):85-90. doi: 10.1177/1078155209354932. Epub 2009 Dec 16. Review.

PMID:
20015929
19.

Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma.

Engert A, del Giglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D.

Onkologie. 2009 Oct;32(10):599-604. doi: 10.1159/000232580. Epub 2009 Sep 14.

PMID:
19816079
20.

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.

Liu Z, Doan QV, Malin J, Leonard R.

Appl Health Econ Health Policy. 2009;7(3):193-205. doi: 10.2165/11314740-000000000-00000.

PMID:
19799473
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk